Trimeric ox40-immunoglobulin fusion protein and methods of use
AssigneeProvidence Health System
InventorsAndrew D. Weinberg, Nicholas P. Morris, Carmen Peters
Life of this patent
Estimating the term…
Abstract
Compositions including a trimeric OX-40 fusion protein are disclosed. Also disclosed are methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells involving administering to the mammal a composition comprising a trimeric OX-40 fusion protein and a pharmaceutically acceptable carrier.
Claims21
A fusion polypeptide comprising in an N-terminal to C-terminal direction:
- an immunoglobulin domain, wherein the immunoglobulin domain comprises an Fc domain;
- a trimerization domain, wherein the trimerization domain comprises an isoleucine zipper domain;
- and
- a receptor binding domain, wherein the receptor binding domain is an OX-40 receptor binding domain,
- and wherein the fusion polypeptide self-assembles into a trimeric fusion protein.
The fusion polypeptide of claim 4, wherein the OX-40 mediated activity is CD4+ T cell proliferation.
A fusion polypeptide comprising in an N-terminal to C-terminal direction:
- a dimerization domain comprising an immunoglobulin Fc domain;
- a trimerization domain comprising an isoleucine zipper domain, wherein the isoleucine zipper domain is a TRAF2 isoleucine zipper, a matrilin-4 isoleucine zipper, or a polypeptide sequence at least 95% identical to the amino acid sequence set forth as SEQ ID NO:4;
- and
- an OX-40 receptor binding domain comprises a polypeptide sequence at least 95% identical to the amino acid sequence set forth as SEQ ID NO:2,
- wherein the fusion polypeptide self-assembles into a trimeric fusion protein.
Dependencies are inferred from the claim text.